Fort Lauderdale, Florida — Lurex Bio announced the formation of its Scientific Advisory Board (SAB), assembling a group of internationally recognized leaders in immunology, oncology, and translational medicine to guide the company’s next phase of platform development.
Lurex Bio is focused on developing non-viral, non-genetic immune engineering technologies designed to address a fundamental limitation in many current therapies: immune evasion rather than immune weakness. In numerous diseases, including cancer, abnormal cells persist not because the immune system cannot act, but because the signals required for recognition and response are absent, distorted, or actively suppressed.